Effects of a home-based pulmonary rehabilitation program in patients with chronic obstructive pulmonary disease in GOLD B group : a pilot study

• Published in: Healthcare (Basel) Vol. 9; no. 5; p. 538
• Main Authors: Vilarinho, Rui, Serra, Lúcia, Coxo, Ricardo, Carvalho, João, Esteves, Cátia, Montes, António Mesquita, Caneiras, Catia
• Format: Journal Article
• Language: English
• Published: Basel MDPI 04-05-2021; MDPI AG
• Subjects: Chronic obstructive pulmonary disease; Chronic respiratory disease; COVID-19; Dyspnea; Electrocardiography; Exercise training; Fitness training programs; Functional outcomes; Home environment; Hospitals; Intervention; patient-reported outcomes; Patients; Rehabilitation; self-management; Portugal
• ISSN: 2227-9032; 2227-9032
• DOI: 10.3390/healthcare9050538

© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Patients with chronic obstructive pulmonary disease (COPD) in the Global Initiative for Chronic Obstructive Lung Disease (GOLD) B group can be included in pulmonary rehabilitation (PR) settings outside the hospitals. This study aimed to explore the feasibility of a home-based pulmonary rehabilitation (HBPR) program and assess its impact on patients with COPD in the GOLD B group. A real-world, pre-post intervention study was conducted with 12 weeks of HBPR (presential home visits and phone calls) using the self-management program Living Well with COPD. The 1-min sit-to-stand test (1MSTS), modified Medical Research Council Questionnaire (mMRC), COPD Assessment Test (CAT), Hospital Anxiety and Depression Scale (HADS), and London Chest Activity of Daily Living (LCADL) were used to assess the impact. Pre-post differences and correlations between changes in outcomes were calculated. In 30 patients (71.6 years, FEV1 (%) 52.8), significant improvements (p < 0.05) were observed on 1MSTS (Pre 17.2, Post 21.2), mMRC (Pre 2.0, Post 1.0), CAT (Pre 16.3, Post 9.9), HADS (Pre 14.4, Post 9.6), and LCADL (Pre 21.0, Post 15.8), with no adverse events reported. When significant, correlations between changes in outcomes were moderate or strong (0.48 ≤ ρ ≤ 0.66). HBPR can be feasible and safe, and it shows the potential to significantly improve outcomes of patients with COPD in the GOLD B group.